Trial | NCT00575861  Report issue

Title

Zileuton and Exhaled Nitric Oxide in Asthmatics
Evaluation of Additive Effects of Zileuton to Advair on Total Exhaled, Bronchial, and Alveolar Nitric Oxide in Asthmatics

  • Phase

    Phase 4

  • Study Type

    Interventional

  • Status

    Completed No Results Posted

  • Intervention/Treatment

    zileuton ...

  • Study Participants

    19
Evaluate the additive role of zileuton 600mg qid to clinically stable asthmatics on Advair 250/50 bid. Since asthma is an endogenous inflammatory disease there usually is increased total exhaled, bronchial and alveolar nitric oxide which are markers of eosinophilic driven pathways of inflammation. The addition of zileuton which is a leukotriene synthesis inhibitor by itself or together with inhaled corticosteroids should reduce nitric oxide gas exchange.
Study Started
Sep 30
2005
Study Completion
Nov 30
2007
Last Update
Dec 20
2007
Estimate

Drug zileuton

zileuton (Zyflo) 600mg qid for 2hr and for 30 days

  • Other names: zyflo

1 Active Comparator

Advair 250/50 (baseline) fluticasone/salmeterol 250/50

Criteria 

Inclusion Criteria:

Non-smoking
Moderate to severe persistent asthmatics
Clinically stable X 6 weeks on Advair 250/50 bid for at least 12 months

Exclusion Criteria:

No leukotriene synthesis inhibitors or receptor antagonists for 6 weeks
No Results Posted